A-803467, A Tetrodotoxin-Resistant Sodium Channel Blocker, Modulates ABCG2-Mediated MDR In Vitro and In Vivo by Anreddy, Nagaraju et al.
Touro Scholar 
Touro College of Pharmacy (New York) 
Publications and Research Touro College of Pharmacy (New York) 
2015 
A-803467, A Tetrodotoxin-Resistant Sodium Channel Blocker, 






See next page for additional authors 
Follow this and additional works at: https://touroscholar.touro.edu/tcopny_pubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Oncology Commons, and the Therapeutics 
Commons 
Recommended Citation 
Anreddy, N., Patel, A., Zhang, Y. K., Wang, Y. J., Shukla, S., Kathawala, R. J., . . . Kumar, P. (2015). A-803467, 
a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. 
Oncotarget, 6(36), 39276-39291. 
This Article is brought to you for free and open access by the Touro College of Pharmacy (New York) at Touro 
Scholar. It has been accepted for inclusion in Touro College of Pharmacy (New York) Publications and Research by 
an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu. 
Authors 
Nagaraju Anreddy, Atish Patel, Yun-Kai Zhang, Yi-Jun Wang, Suneet Shukla, Rishil J. Kathawala, and 
Priyank Kumar 
This article is available at Touro Scholar: https://touroscholar.touro.edu/tcopny_pubs/13 
Oncotarget39276www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 36
A-803467, a tetrodotoxin-resistant sodium channel blocker, 
modulates ABCG2-mediated MDR in vitro and in vivo
Nagaraju Anreddy1,*, Atish Patel1, Yun-Kai Zhang1, Yi-Jun Wang1, Suneet Shukla2, 
Rishil J. Kathawala1, Priyank Kumar1, Pranav Gupta1, Suresh V. Ambudkar2, 
John N. D. Wurpel1, Zhe-Sheng Chen1, Huiqin Guo3,*
1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 
11439, USA
2 Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, 
MD 20892, USA
3Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China
*These authors have contributed equally to this work
Correspondence to:
Huiqin Guo, e-mail: guohuiqin2@163.com
Zhe-Sheng Chen, e-mail: chenz@stjohns.edu
Keywords: multidrug resistance, ABCG2, ABC transporters, non-small cell lung cancer
Received: July 22, 2015  Accepted: October 09, 2015  Published: October 22, 2015
ABSTRACT
ATP-binding cassette subfamily G member 2 (ABCG2) is a member of the ABC 
transporter superfamily proteins, which has been implicated in the development of 
multidrug resistance (MDR) in cancer, apart from its physiological role to remove 
toxic substances out of the cells. The diverse range of substrates of ABCG2 includes 
many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone. ABCG2 
expression has been reported to be significantly increased in some solid tumors and 
hematologic malignancies, correlated to poor clinical outcomes. In addition, ABCG2 
expression is a distinguishing feature of cancer stem cells, whereby this membrane 
transporter facilitates resistance to the chemotherapeutic drugs. To enhance the 
chemosensitivity of cancer cells, attention has been focused on MDR modulators. 
In this study, we investigated the effect of a tetrodotoxin-resistant sodium channel 
blocker, A-803467 on ABCG2-overexpressing drug selected and transfected cell lines. 
We found that at non-toxic concentrations, A-803467 could significantly increase 
the cellular sensitivity to ABCG2 substrates in drug-resistant cells overexpressing 
either wild-type or mutant ABCG2. Mechanistic studies demonstrated that A-803467 
(7.5 μM) significantly increased the intracellular accumulation of [3H]-mitoxantrone 
by inhibiting the transport activity of ABCG2, without altering its expression levels. In 
addition, A-803467 stimulated the ATPase activity in membranes overexpressed with 
ABCG2. In a murine model system, combination treatment of A-803467 (35 mg/kg) 
and topotecan (3 mg/kg) significantly inhibited the tumor growth in mice xenografted 
with ABCG2-overexpressing cancer cells. Our findings indicate that a combination of 
A-803467 and ABCG2 substrates may potentially be a novel therapeutic treatment in 
ABCG2-positive drug resistant cancers.
INTRODUCTION
Multidrug resistance (MDR) is defined as the 
resistance of cancer cells to antineoplastic agents that 
have distinct structures and mechanisms of action [1]. 
Particularly, cancer cells are said to have an MDR 
phenotype when the cells show cross-resistance to 
drugs that are structurally and functionally unrelated to 
the original drug which the cells are resistant [2]. Once 
MDR is acquired, the efficacy of chemotherapeutic drugs 
decreases. MDR is the most significant hindrance to 
successful chemotherapy, and is a main cause of cancer 
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metastasis and relapse [3]. Chemotherapy resistance can 
be primary, which is initially determined by a refractory 
response to the pharmacotherapy, or secondary/acquired, 
which is developed during treatment progression [3].
The potential mechanisms of MDR include 
pharmacokinetic alterations, tumor micro-environmental 
changes, or cancer cell-specific factors that occur at 
different levels due to cellular alterations, which include 
increased drug efflux or decreased drug uptake, drug 
inactivation, drug target modification or apoptosis evasion 
[4]. The key effectors of drug resistance are multidrug 
transporters which can be elevated or hyper-activated 
during the genesis of drug resistant cancers. The ATP-
binding cassette (ABC) multidrug transporters such as 
ABCB1 (MDR1/P-glycoprotein), ABCC1 (MRP1) and 
ABCG2 (BCRP/MXR) are considered to be accountable 
for the majority of drug efflux in human cancers [5]. 
The ABCG2 transporter is a 72-kDa half transporter, 
which was identified from a doxorubicin-selected MCF-7 
human breast cancer cell line [6], human placenta [7], 
and a colon cancer cell line (S1-M1–80) [8]. ABCG2 is 
specifically localized at the apical surface of enterocytes, 
the luminal surface of liver canaliculi, the luminal surface 
of the proximal convoluted tubule of the kidneys, the 
blood–brain barrier (BBB), blood–testis barrier (BTB), 
blood–placental and blood–retinal barriers. Because of its 
localization on the secretory surface of the major organs 
involved in drug transport, ABCG2 alters the ADME 
(absorption, distribution, metabolism and elimination) 
of its substrate drugs. ABCG2 can transport large, 
hydrophobic, positively and negatively charged molecules, 
including cytotoxic compounds such as mitoxantrone 
(MX), topotecan, flavopiridol and methotrexate [9]. 
Although the contribution of ABCG2 in clinical MDR 
has not been completely investigated, some studies have 
described the association between ABCG2 expression 
and poor chemotherapeutic response. Increased ABCG2 
gene expression has also been related to poor response 
to chemotherapy in childhood acute myeloid leukemia 
(AML) and relapsed AML [10, 11]. ABCG2 expression 
has also been reported in leukemia, especially in pediatric 
AML [12]. In addition, increased ABCG2 mRNA has been 
reported in irinotecan treated hepatic metastases compared 
to irinotecan-naive metastases [13]. ABCG2 expression has 
been reported in various solid tumors, such as those present 
in the digestive tract, endometrium and melanoma [14].
Recently, ABCG2 has been recognized as a 
molecular marker for the side population (SP) cells, these 
are putative cancer stem cell CSC population. SP cells are 
identified using dual wavelength flow cytometry combined 
with Hoechst 33342 dye efflux [15]. For human Non-
Small Cell Lung Cancer (NSCLC) cell lines, excluding 
0.03 - 6.1% of the tumor cells which were SP cells [16], 
the presence of a Hoechst dye 33342 showed elevated 
expression of ABCG2, an increased tumorigenicity in 
mice resistant to various chemotherapeutic agents [17]. 
Moreover, Yoh et al. found that positive immunostaining 
for ABCG2 appears to be a predictor of shorter survival in 
patients with advanced NSCLC [18]. Until now, several 
ABCG2 inhibitors with diverse chemical structures have 
been found or developed, but none of them have been 
tested clinically due to concerns of toxicity, safety or the 
pharmacokinetic uncertainty of the compounds [19].
A-803467 is a potent and selective Nav1.8 
sodium channel blocker, which has shown significant 
anti-nociception in animal models of neuropathic and 
inflammatory pain [20]. Previously, ion channel inhibitors 
such as verapamil and quinidine have shown to reverse 
ABC transporter mediated MDR [21]. We, and others, 
have further reported several natural drugs, marine drugs, 
semi-synthetic and synthetic compounds which could 
reverse ABCG2-mediated MDR [22–25]. Therefore, here 
we determine A-803467 as a therapeutic compound to 
enhance the chemosensitivity of conventional anticancer 
drugs through interaction with the ABCG2 transporter.
RESULTS
A-803467 significantly increases the cytotoxicity 
of anticancer drugs which are substrates of 
ABCG2, but not of ABCB1 and ABCC10
Cytotoxicity of A-803467 treatment alone on 
ABCG2-overexpressing cell lines was investigated 
and found to be nontoxic with IC50 values greater than 
10 μM (Supplementary Figure S1). Accordingly, reversal 
concentrations of 2.5 and 7.5 μM, at which no significant 
cytotoxicity was detected for A-803467 alone, were 
chosen for further experiments. HEK293 cells transfected 
with wild-type (HEK293/R482) and mutant (HEK293/
R482G and HEK293/R482T) ABCG2 (Supplementary 
Figure S2) showed significant resistance to MX and 
topotecan compared to HEK293/pcDNA3.1 (Table 1). 
The test compound A-803467 at 7.5 μM significantly 
increased the cytotoxicity of MX and topotecan in 
ABCG2-transfected cell lines (Table 1). In addition, 
the reversal effect of A-803467 on ABCG2-mediated 
MDR was comparable to the effect produced by 5 μM 
of FTC, a known ABCG2 inhibitor. However, A-803467 
did not sensitize ABCG2-transfected cells to cisplatin, 
a non-substrate of ABCG2 (Table 1). Furthermore, the 
reversal effect of A-803467 was also analyzed in parental 
H460, and drug selected ABCG2 overexpressing H460/
MX20 cells. We found similar results where A-803467 
significantly increased the cytotoxicity of MX and 
topotecan in ABCG2 overexpressing H460/MX20 
cells (Table 2). However, A-803467 did not sensitize 
the parental H460 cells to MX and topotecan (Table 2). 
Independently, we also analyzed the effect of A-803467 
on ABCB1- and ABCC10-mediated MDR. We found 
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that A-803467 did not affect the ABCB1- and ABCC10-
mediated MDR in ABCB1 overexpressing HEK293/
ABCB1 cells and ABCC10 overexpressing HEK293/
ABCC10 cells, respectively (Table 3). Together these 
results indicate that A-803467 selectively and significantly 
reverses the ABCG2-mediated MDR.
A-803467 significantly augments the 
intracellular accumulation of [3H]-MX in cells 
overexpressing ABCG2
To investigate the reversal mechanism, we studied 
the effect of A-803467 on the intracellular accumulation 
of [3H]-MX in ABCG2 overexpressing cells. HEK293/
pcDNA3.1 and ABCG2-transfected cells were incubated 
with [3H]-MX, a known substrate of ABCG2, with 
or without A-803467 at different concentrations for 
2 h. A-803467 at 7.5 μM significantly enhanced the 
intracellular [3H]-MX accumulation in ABCG2-transfected 
cells. However, A-803467 did not significantly impact 
the intracellular accumulation in HEK293/pcDNA3.1 
cells (Fig. 1A). These results suggest that the increased 
intracellular levels of [3H]-MX in ABCG2 overexpressing 
cells is due to the inhibitory effect of A-803467 on the 
drug efflux function of the ABCG2 transporter.
A-803467 decreases the efflux of [3H]-MX in cells 
overexpressing ABCG2
We accomplished a time course [3H]-MX efflux, 
with or without A-803467, in ABCG2-transfected cells 
to determine if the increase in intracellular [3H]-MX 
accumulation caused by A-803467 was due to inhibition 
of [3H]-MX efflux. We observed the efflux rate 
of [3H]-MX was significantly higher in ABCG2-
transfected cells as compared with HEK293/pcDNA3.1 
cells. A-803467 at 7.5 μM significantly blocked the 
intracellular [3H]-MX efflux at different time periods 
(0, 30, 60 and 120 min) from ABCG2-transfected cells, 
but not in the parental HEK293/pcDNA3.1 cells. In the 
absence of A-803467, the accumulation of [3H]-MX in 
HEK293/R482 cells at 30, 60 and 120 min were 72.5%, 
62.7% and 52.4%, respectively. When HEK293/R482 
cells were incubated with A-803467, the percentages 
of [3H]-MX at 30, 60 and 120 min were increased to 
86.5%, 84.3% and 72.0%, respectively (Fig. 1B).
Table 1: A-803467 enhances the cytotoxicity of mitoxantrone and topotecan in HEK293/pcDNA3.1 
cells overexpressing the wild-type as well as mutant ABCG2
Treatments










Mitoxantrone 24.8 ± 0.9 1.0 258.5 ± 12.8 10.4# 723.8 ± 12.5 29.1# 808.0 ± 38.2 32.4#
+A-803467 (2.5 μM) 21.5 ± 0.8 0.8 57.5 ± 0.9 2.3* 66.2 ± 1.2 2.6* 74.0 ± 18.9 3.0*
+A-803467 (7.5 μM) 20.4 ± 2.0 0.9 19.5 ± 0.2 0.8* 24.2 ± 1.5 0.9* 34.5 ± 16.7 1.3*
+FTC (5 μM) 21.5 ± 0.8 0.8 17.7 ± 0.1 0.7* 22.4 ± 1.2 0.9 36.5 ± 18.7 1.4*
Topotecan 10.2 ± 2.5 1.0 280.9 ± 30.6 27.5 224.2 ± 12.6 22.0 187.2 ± 19.6 18.4
+A-803467 (2.5 μM) 10.5 ± 3.6 0.9 182.3 ± 23.8 17.9 131.4 ± 21.6 12.9 137.7 ± 15.6 13.5
+A-803467 (7.5 μM) 9.4 ± 3.7 0.9 18.6 ± 4.6 1.8* 15.3 ± 2.8 1.5* 17.4 ± 3.8 1.7*
+FTC (5 μM) 9.8 ± 2.8 0.9 19.8 ± 2.5 1.9* 16.4 ± 2.4 1.6* 16.9 ± 1.4 1.6*
Cisplatin 2945.8 ± 55.9 1.0 2636.0 ± 94.1 0.9 2566.4 ± 88.2 0.8 2745.6 ± 141.8 0.9
+A-803467 (2.5 μM) 2486.7 ± 90.1 0.8 2486.5 ± 125.5 0.8 2478.8 ± 70.6 0.8 2399.4 ± 106.4 0.8
+A-803467 (7.5 μM) 2507.6 ± 186.1 0.8 2377.7 ± 125.3 0.8 2378.2 ± 55.5 0.8 2377.7 ± 125.3 0.8
+FTC (5 μM) 2641.4 ± 84.2 0.8 2396.2 ± 127.02 0.8 2367.5 ± 27.6 0.9 2347.7 ± 43.5 0.8
Data represents the mean IC50 values for each cell line ± SD obtained from three independent sets of experiments. 
Statistical analysis was performed by One-way ANOVA followed by Newman-Keuls Multiple Comparison Test. Statistical 
significance was set at P < 0.05.
*: P < 0.05 versus the control group.
#: P < 0.05 versus the control of HEK293/pcDNA3.1 group. The fold resistance (FR) was determined by dividing the IC50 
value of anticancer drug for HEK293/pcDNA3.1, HEK293/R482, HEK293/R482G and HEK293/R482T, in the absence 
or presence of reversal agents, by the IC50 value of respective anticancer drug for HEK293/pcDNA3.1 in the absence of 
reversal agent. FTC was used as a positive control of ABCG2 inhibitor
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Table 3: A-803467 cannot enhance the cytotoxicity of ABCB1 and ABCC10 substrate anticancer 
agents in HEK293/PCDNA3.1 cells overexpressing ABCB1 and ABCC10
Treatments








Paclitaxel 8.3 ± 0.2 1.0 525.2 ± 20.1 63.2# 95.2 ± 6.1 11.4#
+A-803467 
(7.5 μM) 7.9 ± 0.4 0.9 453 ± 18.9 54.5 77.4 ± 5.6 9.3
+Verapamil 
(5 μM) 8.2 ± 0.6 1.0 9.5 ± 1.5 1.0 * − −
+Cepharanthine 
(2.5 μM) 7.2 ± 0.3 0.8 − − 12.3 ± 2.5 1.4*
Data represents the mean IC50 values for each cell line ± SD obtained from three independent sets of experiments. 
Statistical analysis was performed by One-way ANOVA followed by Newman-Keuls Multiple Comparison Test. Statistical 
significance was set at P < 0.05.
*: P < 0.05 versus the control group.
#: P < 0.05 versus the control of HEK293/pcDNA3.1 group.
The fold resistance (FR) was determined by dividing the IC50 value of the anticancer drug for HEK293/pcDNA3.1, 
HEK293/ABCB1 and HEK293/ABCC10, in the absence or presence of reversal agents, by the IC50 value of the respective 
anticancer drug for HEK293/pcDNA3.1 in the absence of reversal agent. Verapamil and cepharanthine were used as 
positive control inhibitors for ABCB1 and ABCC10 respectively.
Table 2: A-803467 enhances the cytotoxicity of ABCG2 substrate anticancer drugs in H460/MX20 
cells overexpressing ABCG2
Treatments
IC50 ± SD (nM)
H460 FR H460/MX20 FR
Mitoxantrone 58.5 ± 4.2 1.0 7956.0 ± 198.2 135.9#
+A-803467 (2.5 μM) 57.9 ± 1.8 0.9 773.0 ± 18.9 13.2*
+A-803467 (7.5 μM) 55.2 ± 1.3 0.9 345.5 ± 16.7 5.9*
+FTC (5 μM) 55.3 ± 2.3 0.9 363.5 ± 18.7 6.2*
Topotecan 23.4 ± 0.8 1.0 1258.8 ± 47.4 53.3#
+A-803467 (2.5 μM) 20.9 ± 1.2 0.8 445.8 ± 24.7 19.0*
+A-803467 (7.5 μM) 19.3 ± 0.8 0.8 94.4 ± 5.2 4.0*
+FTC (5 μM) 19.7 ± 0.4 0.8 112.5 ± 8.2 4.8*
Cisplatin 2225.5 ± 12.3 1.0 2147.8 ± 24.3 0.9
+A-803467 (2.5 μM) 2147 ± 24.3 0.9 2143.9 ± 42.2 0.9
+A-803467 (7.5 μM) 2209.1 ± 42.3 0.9 2170 ± 72.1 0.9
+FTC (5 μM) 2126.2 ± 50.9 0.9 2172.8 ± 49.9 0.9
Data represents the mean IC50 values for each cell line ± SD obtained from three independent sets of experiments. 
Statistical analysis was performed by One-way ANOVA followed by Newman-Keuls Multiple Comparison Test. Statistical 
significance was set at P < 0.05.
*: P < 0.05 versus the control group.
#: P < 0.05 versus the control of H460 group. The fold resistance (FR) was determined by dividing the IC50 value of the 
anticancer drug for H460 and H460/MX20, in the absence or presence of reversal agents, by the IC50 value of the respective 
anticancer drug for H460, in the absence of reversal agent. FTC was used as a positive control of ABCG2 inhibitor.
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A-803467 does not alter the total expression or 
translocation of ABCG2
To analyze the effect of A-803467 on the ABCG2 
expression, we incubated H460/MX20 cells with A-803467 
(7.5 μM) for 24, 48, and 72 h and found that there was no 
significant change in the expression level of ABCG2 upon 
A-803467 treatment (Fig. 2A). To analyze if A-803467 
causes a translocation of ABCG2 from the plasma membrane 
to the cytoplasm, contributing to a reduction of functional 
ABCG2, we performed an immunofluorescence analysis 
with H460 and ABCG2 overexpressing H460/MX20 cells. 
The results showed that the membrane expression and 
location of ABCG2, in H460/MX20 cells, was not altered 
after treatment with A-803467 (7.5 μM) for 72 h (Fig. 2B).
A-803467 stimulates the ATPase activity 
of ABCG2
Several reversal agents have been reported as an 
inhibitor and/or substrate of ABC transporters [33–36]. To 
determine interaction of A-803467 with ABCG2 ATPase, 
we performed an ATPase assay using membranes of High 
Five insect cells overexpressing ABCG2 with different 
concentrations of A-803467. A-803467 stimulated the 
ATPase activity of ABCG2 in a concentration dependent 
manner, with a maximal stimulation of 2.13-fold greater 
than the basal activity (Fig. 3A). The inset of Fig. 3A 
reveals the concentration of A-803467 required to obtain 
50% stimulation is 0.718 μM. Similarly, we assessed the 
effect of ABCG2 known substrates, topotecan and MX, 
on the ATPase activity of ABCG2. We measured ABCG2-
mediated ATP hydrolysis in the presence of topotecan and 
MX at various concentrations from 0 to 10 μM. Interestingly, 
topotecan and MX stimulated the ATPase activity of ABCG2 
in a concentration dependent manner, with a maximal 
stimulation of 1.81-fold and 2.04-fold greater than the basal 
activity, respectively (Fig. 3B and 3C). In addition, the 
concentration of topotecan and MX required to obtain 50% 
stimulation were 2.60 μM and 2.20 μM, respectively. These 
results suggest A-803467 interacts at the drug-substrate-
binding site and stimulates the ATPase activity of ABCG2.
Docking analysis of A-803467 with human 
ABCG2 homology model
The best-scored docked position of A-803467 within 
the large drug-binding cavity of human ABCG2 is shown 
in Fig 4. The 4-chlorophenyl and furan carboxamide 
substituents of A-803467 were stabilized into a hydrophobic 
pocket formed by nearby residues Phe507, Ala580, Leu581, 
Asn583, Gly625, Leu626, Trp627, Asn629 and His630. The 
4-chlorophenyl ring of A-803467 may be involved in a π-π 
interaction with the phenyl ring of Phe507 (centroid distance, 
4.08 Å). The 3, 5-dimethoxyphenyl group of A-803467 
was stabilized into the large cavity formed by side chains 
of hydrophobic residues Ile412, Tyr464, Ser486, Phe489, 
Ile573, Pro574 and Gly577. Moreover, the 3-methoxyphenyl 
group also entered into a hydrogen bonding interaction with 
Tyr464 (-O•••HO-Tyr464, 1.81 Å).
A-803467 potentiates the anticancer activity 
of topotecan in ABCG2-overexpressing tumor 
xenograft model
Parental H460 cells and drug resistant ABCG2 
overexpressing H460/MX20 cells were implanted into 
Figure 1: Effect of A-803467 on the accumulation and efflux of [3H]-MX in ABCG2-expressing cells. A. A-803467 at 
7.5 μM significantly increased intracellular accumulation of [3H]-MX in ABCG2-expressing cells HEK293/R482, HEK293/R482G and 
HEK293/R482T cells.*: P < 0.05 versus the control group. #: P < 0.05 versus the control of HEK293/pc DNA 3.1 group. B. The efflux 
activity of ABCG2 was significantly inhibited by 7.5 μM of A-803467 at 0, 30, 60, and 120 min of treatment in HEK293/R482 cells. 
*: P < 0.05 versus the HEK293/R482 group.
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athymic nude mice to create xenograft tumor models to 
analyze the efficacy of A-803467 to circumvent resistance 
to topotecan in vivo. A 35 mg/kg oral dose of A-803467 
was chosen based on our preliminary study (data not 
shown) and showed no noticeable toxicity in the male 
NCR nude mice. Topotecan alone at 3 mg/kg i.p. dose 
demonstrated significant growth retardation in the parental 
H460 xenografts as well as ABCG2 overexpressing H460/
MX20 xenografts (Fig. 5A-5D). However, the H460 
tumor xenografts exhibited a more dramatic reduction 
when compared to H460/MX20 xenografts due to lack of 
ABCG2 expression in H460 tumors results in increased 
concentration of topotecan when compared to H460/
MX20 tumors. The tumor growth rate of the xenograft 
mice implanted with ABCG2 overexpressing cells 
was significantly reduced in the A-803467-topotecan 
combination group as compared to the vehicle, A-803467 
alone, and topotecan alone groups (Fig. 5A). Not only 
was the H460/MX20 tumor growth minimized, but also 
the size and weight of the tumors were significantly 
reduced in the combination treatment group (Fig. 5B and 
6A). It should be mentioned that A-803467 alone had no 
significant effect on the growth rate of H460 (Fig. 5C and 
6B) and H460/MX20 (Fig. 5A and Fig. 6A) xenografts. 
Furthermore, topotecan with or without A-803467 did not 
produce any apparent toxicity or weight loss (Fig. 6C). 
Overall, A-803467 did not present any increased toxicity 
in the mice, yet improved the efficacy of topotecan 
in the ABCG2 overexpressing H460/MX20 resistant 
xenograft model.
DISCUSSION
ABCG2 plays an important role in development 
of drug resistance in clinical medicine. There is a 
strong correlation between ABCG2 overexpression and 
development of drug resistance in several cancer cells, 
Figure 2: Effect of A-803467 on ABCG2 expression and the subcellular localization of ABCG2. A. Effect of A-803467 at 
7.5 μM on the expression level of ABCG2 in H460/MX20 cell line. The protein levels of ABCG2 were normalized to those of actin. Values 
show the mean ± SD of 3 assays. B. Effect of A-803467 treatment on the subcellular localization of ABCG2 in H460/MX20 cell. ABCG2 
staining is shown in green. DAPI (blue) counterstains the nuclei.
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including NSCLC, colon carcinoma, hepatocellular 
carcinoma (HCC) and breast cancer [37]. In the past four 
years, there has been rising evidence for overexpression 
of ABCG2 in hematologic malignancies and solid tumors; 
in these studies, ABCG2 overexpression significantly 
correlated with decreased patient survival [38]. The 
ABCG2 transporter is present in certain populations 
of cancer stem cells and normal primitive stem cells, 
increasing the likelihood of overexpression and thus 
resistance to various anticancer drugs [39–41]. Sensitizing 
these cells to anticancer drugs with the help of ABC 
transport reversal agents can effectively eradicate the 
tumor population, leading to better clinical outcomes for 
patients.
A wide variety of compounds that can inhibit 
ABCG2 have been comprehensively studied [42]. ABCG2 
inhibitors include, fumitremorgin C (FTC), the FTC 
analogue Ko143, the acridone carboxamide derivative 
GF120918, anti-HIV protease inhibitors nelfinavir and 
ritonavir, the dietary flavonoids chrysin and biochanin 
A, the tyrosine kinase inhibitors gefitinib and imatinib 
[43], and some herbal extracts [44]. ABCG2 inhibitors 
such as Ko143, GF120918 and gefitinib are highly 
potent with their IC50 values in nano molar range. FTC 
and Ko143 are highly selective in inhibiting the ABCG2 
transporter, whereas rest of the compounds seems to be 
general inhibitors of ABC transporters [42]. The selective 
ABCG2 inhibitors such as FTC and Ko 143 are effective 
only in vitro [45]. Several ABCG2 inhibitors have been 
identified but none of them are in clinical use due to 
toxicity and pharmacokinetic uncertainty. Hence there is 
still an ongoing search for a safer and specific inhibitor of 
the ABCG2 transporter.
In order to identify novel inhibitors of ABCG2, a 
cell based assay using MTT in ABCG2 overexpressing 
H460/MX20 cells was used to screen libraries of 
compounds. Similar approaches have been carried out 
by many researchers to obtain the inhibitors specific 
Figure 3: Effect of A-803467, MX and topotecan on the ATPase activity of ABCG2. A. Vanadate-sensitive ATPase activity 
of ABCG2 in membrane vesicles was determined with different concentrations of A-803467, as described in materials and methods. 
A-803467 showed a concentration dependent increase in ATPase activity. B. Effect of MX on the ATPase activity of ABCG2. C. Effect of 
topotecan on the ATPase activity of ABCG2. All values are the mean ± SD of 3 assays.
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to ABCG2 [46]. In our study, we screened several 
tyrosine kinase inhibitors, synthetic small molecule 
inhibitors[47, 51] and ion channel inhibitors for activity in 
ABCG2 overexpressed cells and found that A-803467 was 
effective in inhibiting ABCG2 mediated drug resistance at 
micro molar concentrations.
One of the major findings of this study was that 
A-803467 significantly increased the sensitivity of 
ABCG2 overexpressing H460/MX20 cells to ABCG2 
substrates such as topotecan and MX (Table 2). In 
addition, A-803467 did not enhance the cytotoxic effect 
of cisplatin, a drug that is not a substrate for the ABCG2 
transporter, further demonstrating the specificity of 
A-803467. Moreover, previous studies have found that 
the 482nd position in ABCG2 is a hot spot for mutation, 
Arg482 to Gly482 or Thr482 mutant variants of ABCG2 
have shown to be significant in substrate specificity as well 
as the potency of ABCG2 antagonist [26, 52]. Robey et al. 
further reported that the activity of the ABCG2 transporter 
varies in these mutant cell lines. For example, novobiocin 
only antagonizes wild-type ABCG2 but does not show any 
effect in mutant variants. However, FTC has been shown 
to inhibit both wild-type as well as mutant ABCG2 [26]. 
This study has revealed that similar to FTC, A-803467 
significantly enhances the chemosensitivity of ABCG2 
substrates in both the cells with wild-type Arg482 and 
mutant Gly482 or Thr482 of ABCG2 (Table 1). These 
results clearly demonstrate the A-803467 activity in 
the aforementioned mutants of ABCG2. Furthermore, 
A-803467 could not reverse ABCB1- and ABCC10-
mediated drug resistance in cells overexpressing ABCB1 
and ABCC10 transporters (Table 3); thus implying that the 
reversal effect of A-803467 is ABCG2 specific.
In order to find the possible mechanism of action 
of A-803467, we investigated its effect on the ABCG2 
expression. In this study, A-803467 at 7.5 μM did not 
significantly alter the expression of the ABCG2 protein 
in H460/MX20 cells (Fig. 2A). In addition, A-803467 
Figure 4: Predicted binding position of A-803467 with homology modeled ABCG2. A. Docked position of A-803467 within 
the drug-binding site of human ABCG2. Important residues are depicted as sticks with the atoms colored: carbon – green, hydrogen – white, 
nitrogen – blue, oxygen – red, sulfur – yellow. A-803467 is shown as ball and stick model with the same color scheme as above, except carbon 
atoms are represented in orange and chlorine in dark green. Ring centroids were represented as dark-green dots. Dotted yellow lines indicate 
hydrogen bonds. B. A two-dimensional ligand − receptor interaction diagram with important interactions observed in the docked complex 
of A-803467 with the drug-binding site residues of human ABCG2 is shown. The amino acids within 4 Å are shown as colored bubbles, red 
indicates negative charge, cyan indicates polar, and green indicates hydrophobic residues. Hydrogen bonds are shown by the purple dotted 
arrow, while π-π stacking aromatic interactions are shown by green lines. C. Location of predicted binding position of A-803467 (carbon 
atoms are represented in orange) and topotecan (carbon atoms are represented in purple) within transmembrane domain of ABCG2.
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did not translocate the ABCG2 protein from the cell 
membrane after 72 h of treatment (Fig. 2B). This clearly 
demonstrates that reversal of MDR by A-803467 is 
unlikely due to its decreasing ABCG2 protein expression 
or a translocation and most likely due to the interaction 
with ABCG2. Further functional analysis was performed 
by measuring the intracellular accumulation of [3H]-MX 
in wild-type HEK293/R482, mutant HEK293/R482T, 
and mutant HEK293/R482G cells (Fig. 1A). In addition, 
we also investigated the effect of A-803467 on the efflux 
of [3H]-MX in wild-type HEK293/R482 cells (Fig. 1B). 
A-803467 at 7.5 μM produced a significant increase in 
accumulation of MX by inhibiting the efflux function 
in the forenamed cell lines but not in parental HEK293/
pcDNA3.1 cells.
To further understand the interaction of A-803467 
with ABCG2, we performed an ATPase assay using 
ABCG2 overexpressed membranes. The majority of TKIs 
that interact with the ABC drug transporters stimulate ATP 
hydrolysis [53] and the fact that A-803467 stimulates the 
ATP hydrolysis of ABCG2 in a concentration dependent 
manner (Fig. 3A) indicates that it behaves similar to other 
known substrates (Fig. 3B and 3C) of ABCG2 transporter, 
such as MX and topotecan. These results further prove 
that A-803467 not only interacts directly with the ABCG2 
transporter, but may also be a competitive inhibitor of 
the transporter.
To identify the molecular interaction of A-803467 
with the ABCG2 transporter, docking simulation 
was performed at various sites of the human ABCG2 
homology model. The crystal structure of human ABCG2 
transporter is not completely elucidated. Comparing the 
docking scores shown in Table 4, the most favorable 
binding site was identified as site-1. Molecular docking 
of topotecan, a well-known ABCG2 substrate, at the 
same site of ABCG2 was performed. The docking 
Figure 5: The effect of A-803467 on H460 and H460/MX20 tumor xenograft growth rate. A. Changes in tumor volume with 
time in H460/MX20 xenograft are shown. Each point on line graph represents the mean tumor volume (mm3) at each particular day after 
implantation. B. A representative picture of the excised H460/MX20 tumors from the different mice on the 18th day after implantation. 
C. Changes in tumor volume with time in H460 xenograft are shown. D. A representative picture of the excised H460 tumors sized from 
different mice is shown on the 18th day after implantation. Each column represents the mean determinations and the bars represent SEM of 
6 mice. *: P < 0.05 versus the vehicle group. #: P < 0.05 versus the topotecan group.
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score of topotecan (-5.57 kcal/mol) is much higher than 
that of A-803467 (-8.07 kcal/mol). The lower docking 
score indicates stronger interaction between A-803467 
to ABCG2 (Fig. 4). Moreover, molecular structure of 
A-803467 also exhibited the pharmacophoric features 
such as hydrophobic groups, aromatic ring centers (phenyl 
ring and furan ring) and hydrogen bond acceptors that 
have been reported as essential for ABCG2 inhibition [54]. 
Overall, this molecular simulation will provide clues to 
optimize further derivatives of ABCG2 inhibitors.
To our knowledge, this is the first study that 
demonstrates the combined effect of A-803467 with 
anticancer drug topotecan in NCR nude mice implanted 
with ABCG2 overexpressing H460/MX20 cells. The dose 
and route of administration of A-803467 (35 mg/kg, p.o) 
was chosen based on our preliminary study (data not 
shown). A-803467 was administered on the 2nd and 3rd day 
before administration of topotecan to compensate for its 
high binding to plasma proteins. Jarvis et al., reported that 
A-803467 was highly bound (98.7%) to plasma proteins 
in rats [20]. The in vivo study results indicated that 
A-803467 in combination with topotecan, significantly 
decreased the tumor growth in mice implanted with 
ABCG2 overexpressing H460/MX20 cells (Fig 5A, 5B 
and 6A). A-803467 effectively restored the sensitivity of 
tumors overexpressing ABCG2 transporter to topotecan 
without having any significant effect on tumors lacking 
ABCG2 expression (Fig. 5C, 5D and 6B). Furthermore, 
A-803467 alone, or in combination with topotecan, did 
not produce significant observable toxicity or weight loss 
during the study period (Fig. 6C). The safety profile of 
A-803467 in humans is not investigated yet, but currently 
A-803467 is in pre-clinical testing stage for neuropathic 
and inflammatory pain [20]
Figure 6: The effect of A-803467 on H460 and H460/MX20 tumor weight. A. Mean H460/MX20 tumor weight (n = 6). 
B. Mean H460 tumor weight (n = 6). C. Changes in mean body weight before and after treatment for xenograft model. *: P < 0.05 versus 
the vehicle group; #: P < 0.05 versus the topotecan group.
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ABCG2 is responsible for the “side population” 
(SP) phenotype, frequently used in the identification and 
isolation of cancer stem cells (CSCs). ABCG2 has also 
been suggested as a prognostic biomarker as well as a 
novel therapeutic target for the eradication of CSCs [40]. 
Presently, conventional chemotherapeutic anticancer 
agents target highly proliferative tumor cells. The CSCs 
survive such chemotherapy due to their high expression 
of ABCG2 transporter, mediating their chemoresistance, 
and ultimately leading to tumor relapse and metastasis. 
Completely eradicating cancer stem cells by overcoming 
the resistance to chemotherapy, mediated by ABCG2, 
would be a new targeted therapeutic strategy. This study 
suggests that combined therapy of A-803467 with ABCG2 
substrates may provide a more effective way of sensitizing 
ABCG2-mediated MDR and possibly eliminating CSCsIn 
conclusion, A-803467, a tetrodotoxin resistant sodium 
channel blocker, effectively inhibits membrane ABCG2 
function, without affecting its expression or cellular 
location and re-sensitizes the ABCG2 substrates in 
ABCG2 overexpressing cells. A-803467, even at micro 
molar concentrations, stimulates ATP hydrolysis of the 
ABCG2 transporter with strong binding interactions 
at the transmembrane site of the transporter. A-803467 
significantly potentiates the antitumor efficacy of 
topotecan in tumor xenograft nude mice. Therefore, it 
is likely that A-803467, in combination with anticancer 
agents that are ABCG2 substrates, would be very useful in 
the treatment of certain drug resistant cancers.
MATERIALS AND METHODS
Chemicals
A-803467 was purchased from Alomone Labs 
(Jerusalem, Israel). MX, topotecan, vincristine, cisplatin, 
verapamil, dimethyl sulfoxide (DMSO), ammonium 
molybdate, MES hydrate, antimony potassium 
tartrate, sodium azide, N-methyl-D-glucamine and 
3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyltetrazolium 
bromide (MTT) were purchased from Sigma Chemical 
Co (St. Louis, USA). [3H]-MX (4 Ci/mmol) was 
purchased from Moravek Biochemicals, Inc (Brea, 
CA). Dulbecco’s modified Eagle’s medium (DMEM), 
fetal bovine serum (FBS), penicillin/streptomycin and 
trypsin 0.25% were purchased from Hyclone (Waltham, 
MA). Monoclonal antibodies BXP-21 (against ABCG2), 
sc-8432 (against actin) and horseradish peroxidase-
labeled anti-mouse IgG were purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA). Alexa flour 
488-conjugated goat anti-mouse IgG was purchased 
from Molecular Probes (Eugene, OR). Full-Range 
Rainbow Molecular weight marker was purchased from 
GE Healthcare Life Sciences (Pittsburgh, PA). Potassium 
phosphate, EGTA and ATP were purchased from 
AMRESCO (Solon, OH). Sulfuric acid solution (37 N) 
was purchased from Fisher Scientific (Pittsburgh, PA). 
KCl was purchased from Avantor Performance Materials 
(Center Valley, PA). Ouabain was purchased from Enzo 






 Site-4d –2.83 NA
Binding energies of A-803467 and topotecan within each of the predicted binding sites of ABCG2.
aSite grid generated using Arg482:
bSite grid generated using Asn629:
cSite grid generated using Arg383:
dSite grid generated using Leu241 and Gly832.
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Life Sciences, Inc. (Farmingdale, NY). Dithiothreitol 
was purchased from Promega Corporation (Madison, 
WI). MgCl2 was purchased from EMD Millipore 
(Billerica, MA). Ascorbic acid was purchased from VWR 
International (West Chester, PA). Sodium orthovanadate 
was purchased from Alfa Aesar (Ward Hill, MA). 
Cepharanthine was provided by Kakenshoyaku Co. 
(Tokyo, Japan). Fumitremorgin C (FTC) was provided 
by Dr. Susan E. Bates (Bethesda, USA).
Equipment
OPSYS microplate reader was purchased from 
Dynex Technologies (Chantilly, VA). Packard TRI-CARB1 
1900CA liquid scintillation analyzer was purchased from 
Packard Instrument Company, Inc (Downers Grove, IL). 
Nikon eclipse TE2000-S fluorescence microscope was 
purchased from Nikon (Melville, NY).
Cell lines and cell culture
HEK293/pcDNA3.1, wild-type HEK293/R482, 
mutant HEK293/R482T and mutant HEK293/R482G 
cells were established by transfecting HEK293 cell with 
either the empty pcDNA3.1 vector or pcDNA3.1 vector 
containing a full-length ABCG2, with coding arginine (R), 
threonine (T), or glycine (G) at amino acid position 482, 
respectively, after selection with G418 and maintained in 
medium with 2 mg/ml of G418 [26]. HEK293/ABCB1 and 
HEK293/ABCC10 cell lines were generated by selection 
with G418 (2 mg/ml) after transfecting HEK293 cell with 
ABCB1 vector or ABCC10 vector, respectively [27]. The 
human lung cancer cell line H460, and its MX-selected 
derivative ABCG2-overexpressing cell line H460/MX20 
were used in the study [28]. All cell lines were maintained 
in RPMI 1640 or DMEM medium, containing 10% fetal 
bovine serum and 1% penicillin/streptomycin and cultured 
in an incubator at 37°C with 5% CO2.
Cell viability assay
Cytotoxicity tests and reversal experiments were 
performed using the MTT colorimetric assay as described 
previously [29]. Cells were harvested and resuspended 
in a final concentration of 6 × 103 cells/well for HEK293/
pcDNA3.1, HEK/ABCB1, HEK/ABCC10, HEK293/R482, 
HEK293/R482G and HEK293/R482T cells, and 4 × 103 
cells/well for H460 and H460/MX20 cells. Cells were seeded 
evenly into 96-well plates. To determine the cytotoxicity 
of A-803467, different concentrations of drug were added 
into the each well after 24 h of incubation. To determine the 
reversal capability of A-803467, various concentrations of 
chemotherapeutic drugs were added into designated wells 
after 2 h preincubation with A-803467, FTC, verapamil or 
cepharanthine. After 68 h of drug incubation, MTT reagent 
(4 mg/mL) was added. The plates were incubated for an 
additional 4 h, the supernatant was discarded and 100 μl of 
DMSO were added to dissolve the formazan crystals. Cell 
viability was measured at a wavelength of 570 nm. All the 
experiments were repeated at least 3 times, and the mean and 
standard deviation (SD) values were calculated.
[3H]-MX accumulation and efflux assay
We examined the effect of A-803467 on the 
intracellular accumulation and efflux of [3H]-MX in 
ABCG2-overexpressing cells as previous described [30]. 
Briefly, the cells (5 × 106/cells) were resuspended and 
incubated in the RPMI 1640 medium in the presence or 
absence of A-803467 (7.5 μM) or FTC (5 μM) at 37°C 
for 2 h. Cells were then incubated with 0.01 μM [3H]-
MX containing medium for additional 2 h at 37°C, with 
or without A-803467 (7.5 μM) or FTC (5 μM), and 
subsequently washed twice with ice-cold PBS. For the 
accumulation assay, cells were lysed by the 10 mM lysis 
buffer (pH 7.4, containing 1% Triton X-100 and 0.2% 
SDS) and then placed in scintillation fluid. For the efflux 
assay, the suspended cells were then cultured in [3H]-MX 
free medium, with or without A-803467 (7.5 μM) or FTC 
(5.0 μM) at 37°C. The aliquots of cells were harvested 
at the indicated times (0, 30, 60, and 120 min), and then 
washed with ice-cold PBS and transferred to respective 
scintillation vials. The radioactivity was measured using the 
Packard TRI-CARB1 190`A liquid scintillation analyzer.
Western blot analysis
Cell lysates were prepared as described previously 
[31]. Equal amounts of total cell lysates (30 μg protein) 
were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and electrophoretically 
transferred onto polyvinylidene fluoride (PVDF) 
membranes. After incubation in a blocking solution (5% 
milk) for 1 h at room temperature, the membranes were 
immunoblotted overnight with primary monoclonal 
antibodies against actin at 1:1000 dilution or ABCG2 at 
1:500 dilution at 4°C, and were then further incubated 
for 2 h at room temperature with horseradish peroxide 
(HRP)-conjugated secondary antibody (1:1000 dilution). 
The protein–antibody complex was detected by enhanced 
chemiluminescence detection system (Amersham, NJ).
Immunofluorescence analysis
For immunofluorescence analysis, H460 and 
H460/MX20 cells were seeded in 24 well plates. Cells 
were incubated with or without A-803467 (7.5 μM) 
for 72 h. Thereafter, cells were washed with PBS and 
fixed with 4% paraformaldehyde for 15 min at room 
temperature and then rinsed with PBS three times, 
followed by permeabilization with 1% triton X-100 for 
10 min at 4°C. Cells were again washed for three times 
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with PBS, and then blocked with 2 mg/ml of BSA for 
1 h at 37°C. Fixed cells were incubated with monoclonal 
antibody against ABCG2 (BXP 21) (1:50) for 16 h at 
4°C, followed by three washes with PBS. The cells were 
then further incubated with Alexa flour 488 goat anti-
mouse IgG (1:60) for 1 h at 37°C. DAPI was used for 
nuclear counterstaining. Immunofluorescence images 
were taken with a Nikon fluorescence microscope.
ABCG2 ATPase assay
The Vi-sensitive ATPase activity of ABCG2 in the 
membrane vesicles of High Five insect cells was measured 
as previously described. The membrane vesicles (100 μg 
protein/ml) were incubated in ATPase assay buffer with 
or without 0.3 mM vanadate at 37°C for 5 min and then 
incubated with different concentrations of A-803467 
ranging from 0 to 80 μM, topotecan, and MX (0 – 30 μM), 
at 37°C for 3 min. The ATPase reaction was induced by 
the addition of 5 mM Mg-ATP, and the total volume was 
0.1 mL. After incubation at 37°C for 20 min, the reactions 
were stopped by loading 0.1 mL of 5% SDS solution. 
The liberated inorganic phosphate (Pi) was measured as 
described previously [28]
Molecular modeling
A-803467 was prepared as ligands for docking 
simulation onto human ABCG2 homology model following 
the same protocols as previously described [32]. All grids of 
ABCG2 were prepared and generated as per our previous 
protocols [32]. Grid-1 generated using residue Arg482 as the 
centroid had the highest docking score; therefore, docking 
discussion was based on binding position of A-803467 at this 
site. Glide v6.0 (Schrödinger, LLC, New York, NY, 2013) 
docking protocol was followed with the default parameters. 
Top scoring conformation was used for graphical analysis. 
All computations were carried out on a Dell 490n dual 
processor with Linux OS (Ubuntu 12.04 LTS).
Animals
Athymic NCr (nu/nu) nude mice, weighing 18 to 
22 g (Taconic Farms, NCRNU-M, Homozygous, Albino 
color), were used for the ABCG2 xenograft models. 
All animals were provided with sterilized water and rodent 
chow ad libitum and maintained with an alternating 12 h 
light/dark cycle. All the experiments were approved by the 
Institutional Animal Care & Use Committee (IACUC) of 
St. John’s University, and were carried out in accordance 
with the guidelines from Animal Welfare Act and The U.S. 
Public Health Service.
Nude mouse MDR xenograft models
The ABCG2-overexpressing NSCLC cell H460/
MX20 xenograft mouse models were established as 
previously explained [41]. H460/MX20 cells (6 × 106) 
and H460 cells (4 × 106) were injected subcutaneously 
under the right and left armpit regions of the nude mice, 
respectively. We performed a pilot study using three 
different doses of A-803467 (17.5, 35 and 70 mg/kg) and 
we found that 35 mg/kg dose was effective in increasing 
the topotecan sensitivity in tumors without significantly 
increase toxicity, therefore 35 mg/kg dose was used 
throughout the following study.
The mice were randomized into 4 groups (n = 6) 
when the tumors attained a mean diameter of 0.5 cm 
(day 0), and then received treatments as follows: (a) 
Vehicle (10% N-methyl pyrrolidine (NMP) in PEG-300, 
p.o., every 2nd and 3rd day; total 12 times), (b) A-803467 
diluted in 10% NMP in PEG-300 (35 mg/kg, p.o., every 
2nd and 3rd day; total 12 times), (c) Topotecan (3.0 mg/
kg, i.p., every 3rd day; total 6 times), and (d) A-803467 
(35 mg/kg, every 2nd and 3rd day; total 12 times, given 1 h 
before topotecan) + topotecan (3.0 mg/kg, i.p., every 3rd 
day: total 6 times). The body weights of the mice were 
monitored and the two perpendicular diameters of tumors 
(A and B) were recorded every 4th day, and tumor volumes 
(V) were calculated according to the following formula 
described previously [41].
The ratio of growth inhibition (IR) described 
previously [41] was estimated according to the formula 
given below.
Statistical analysis
All experiments were repeated at least three times 
and the differences were determined by using the one-
way ANOVA followed by Newman-Keuls post hoc test 
for comparing multiple groups with one variable in the 
following experiments: cell viability assay, accumulation 
assay, quantification of immunoblotting and tumor weight 
measurement. Statistical analysis was performed by two 
way ANOVA followed by Bonferroni post hoc test for 
comparing multiple groups with more than one variable in 
the following experiments: efflux assay, tumor growth rate 
measurement and body weight measurement. Statistical 
analysis was performed by un-paired student t-test for 
comparing two groups in immunoblotting. Statistical 
significance was set at P < 0.05. Statistical analysis 
was performed using GraphPad Prism version 6.01 for 
Windows (GraphPad Software, La Jolla, CA).
ACKNOWLEDGMENTS
We thank Dr. Mark F. Rosenberg and Dr. Zsolt 
Bikadi (Manchester Interdisciplinary Biocentre, 131 
Oncotarget39289www.impactjournals.com/oncotarget
Princess Street, University of Manchester, Manchester, 
M17DN, UK) for providing coordinates of the ABCG2 
homology model. We are thankful to Drs. Susan E. 
Bates and Robert W. Robey (NCI, NIH) for providing us 
HEK293/pcDNA3.1 (parental), HEK293/R482, HEK293/
R482G and HEK293/R482T, H460 and H460/MX20 
cell lines. We thank Anna Maria Barbuti (St. John’s 
University, NY) for her critical reading and editing of the 
article. This work was supported by St. John’s University 
and NIH grant (No: CA143701) to ZS. Chen, and Wu 
Jieping Medical Foundation ( No: 320.6750.1297) to 
H. Guo.
CONFLICTS OF INTEREST
The authors have declared that no potential conflict 
of interest exists.
Author contributions
Conceived and designed the experiments: NA, ZSC, 
HG. Performed the experiments: NA, HG, AP, YKZ, YJW, 
SS, RJK, PK, PG. Analyzed the data: NA, HG, JNDW. 
Wrote the paper: HG, NA, ZSC, JNDW and SVA .
REFERENCES
1. Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug 
resistance in ovarian cancer. Cancer. 1987; 60:2075–2080.
2. Kaye SB. The multidrug resistance phenotype. British 
journal of cancer. 1988; 58:691–694.
3. Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance 
in cancer chemotherapeutics: Mechanisms and lab 
approaches. Cancer letters. 2014; 347:159–166.
4. Zinzi L, Capparelli E, Cantore M, Contino M, 
Leopoldo M, Colabufo NA. Small and Innovative 
Molecules as New Strategy to Revert, MDR. Frontiers in 
oncology. 2014; 4:2.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in 
cancer: role of ATP-dependent transporters. Nature reviews 
Cancer. 2002; 2:48–58.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, 
Rishi AK, Ross DD. A multidrug resistance transporter 
from human MCF-7 breast cancer cells. Proceedings of 
the National Academy of Sciences of the United States of 
America. 1998; 95:15665–15670.
7. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, 
Dean M. A human placenta-specific ATP-binding cassette 
gene (ABCP) on chromosome 4q22 that is involved in 
multidrug resistance. Cancer research. 1998; 58:5337–5339.
8. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, 
Cristensen B, Brangi M, Greenberger L, Dean M, 
Fojo T, Bates SE. Molecular cloning of cDNAs which 
are highly overexpressed in mitoxantrone-resistant cells: 
demonstration of homology to ABC transport genes. Cancer 
research. 1999; 59:8–13.
9. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. 
Overexpression of wild-type breast cancer resistance 
protein mediates methotrexate resistance. Cancer research. 
2002; 62:5035–5040.
10. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, 
Sauerbrey A. BCRP gene expression is associated with a 
poor response to remission induction therapy in childhood 
acute myeloid leukemia. Leukemia. 2002; 16:1443–1447.
11. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, 
Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R, 
Sonneveld P. Increased expression of the breast cancer 
resistance protein (BCRP) in relapsed or refractory acute 
myeloid leukemia (AML). Leukemia. 2002; 16:833–839.
12. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, 
Morabito F, Santini V, Petrini M. Evaluation of BCRP and 
MDR-1 co-expression by quantitative molecular assessment 
in AML patients. Leuk Res. 2004; 28:367–372.
13. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, 
Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, 
Pommier Y, Pau B, Martineau P, Del Rio M. ABCG2 
overexpression in colon cancer cells resistant to SN38 
and in irinotecan-treated metastases. Int J Cancer. 2004; 
109:848–854.
14. Diestra JE, Scheffer GL, Catala I, Maliepaard M, 
Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA. 
Frequent expression of the multi-drug resistance-associated 
protein BCRP/MXR/ABCP/ABCG2 in human tumours 
detected by the BXP-21 monoclonal antibody in paraffin-
embedded material. J Pathol. 2002; 198:213–219.
15. Wan P, Zhou QW, Ma ZQ, Chen PD, Liu DJ. [Molecular 
markers linked to dwarf gene Rht3 in wheat]. Yi Chuan 
Xue Bao. 2001; 28:1028–1033.
16. Ho MM, Ng AV, Lam S, Hung JY. Side population in 
human lung cancer cell lines and tumors is enriched with 
stem-like cancer cells. Cancer Res. 2007; 67:4827–4833.
17. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, 
Di Virgilio A, Conticello C, Ruco L, Peschle C, 
De Maria R. Identification and expansion of the tumorigenic 
lung cancer stem cell population. Cell Death Differ. 2008; 
15:504–514.
18. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, 
Nishiwaki Y, Kodama T, Suga M, Ochiai A. Breast cancer 
resistance protein impacts clinical outcome in platinum-
based chemotherapy for advanced non-small cell lung cancer. 
Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2004; 10:1691–1697.
19. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, Peng H. New 
use for an old drug: inhibiting ABCG2 with sorafenib. 
Mol Cancer Ther. 2012; 11:1693–1702.
20. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, 
Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, 
Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, 
Oncotarget39290www.impactjournals.com/oncotarget
Chu K, et al. A-803467, a potent and selective Nav1.8 
sodium channel blocker, attenuates neuropathic and 
inflammatory pain in the rat. Proc Natl Acad Sci U S A. 
2007; 104:8520–8525.
21. Yusa K, Tsuruo T. Reversal mechanism of multidrug 
resistance by verapamil: direct binding of verapamil to 
P-glycoprotein on specific sites and transport of verapamil 
outward across the plasma membrane of K562/ADM cells. 
Cancer Res. 1989; 49:5002–5006.
22. Zhang H, Zhang YK, Wang YJ, Kathawala RJ, Patel A, 
Zhu H, Sodani K, Talele TT, Ambudkar SV, Chen ZS, 
Fu LW. WHI-P154 enhances the chemotherapeutic effect of 
anticancer agents in ABCG2-overexpressing cells. Cancer 
Sci. 2014; 105:1071–1078.
23. Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, 
Patel A, Talele TT, Chen ZS, Fu LW. AST1306, a potent 
EGFR inhibitor, antagonizes ATP-binding cassette 
subfamily G member 2-mediated multidrug resistance. 
Cancer letters. 2014; 350:61–68.
24. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, 
Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, 
Fu LW, Chen ZS. Sildenafil reverses ABCB1- and ABCG2-
mediated chemotherapeutic drug resistance. Cancer 
research. 2011; 71:3029–3041.
25. Tan KW, Killeen DP, Li Y, Paxton JW, Birch NP, 
Scheepens A. Dietary polyacetylenes of the falcarinol type 
are inhibitors of breast cancer resistance protein (BCRP/
ABCG2). European journal of pharmacology. 2014; 
723:346–352.
26. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, 
Risbood M, Poruchynsky MS, Bates SE. Mutations at 
amino-acid 482 in the ABCG2 gene affect substrate and 
antagonist specificity. British journal of cancer. 2003; 
89:1971–1978.
27. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, 
Kotova E, Kruh GD. Characterization of the transport 
properties of human multidrug resistance protein 7 (MRP7, 
ABCC10). Mol Pharmacol. 2003; 63:351–358.
28. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, 
Litman T, Bates SE. A functional assay for detection of the 
mitoxantrone resistance protein, MXR (ABCG2). Biochim 
Biophys Acta. 2001; 1512:171–182.
29. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, 
Mitchell JB. Evaluation of a tetrazolium-based semiauto-
mated colorimetric assay: assessment of chemosensitivity 
testing. Cancer Res. 1987; 47:936–942.
30. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, 
Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib 
reverses chemotherapeutic multidrug resistance mediated by 
ABCG2 efflux transporter in vitro and in vivo. Biochemical 
pharmacology. 2014; 89:52–61.
31. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, 
Singh S, Ambudkar SV, Stephani R, Chen ZS. PD173074, 
a selective FGFR inhibitor, reverses ABCB1-mediated 
drug resistance in cancer cells. Cancer chemotherapy and 
pharmacology. 2013; 72:189–199.
32. Kathawala RJ, Chen JJ, Zhang YK, Wang YJ, Patel A, 
Wang DS, Talele TT, Ashby CR Jr, Chen ZS. Masitinib 
antagonizes ATP-binding cassette subfamily G member 
2-mediated multidrug resistance. International journal of 
oncology. 2014; 44:1634–1642.
33. Dai Cl, Tiwari AK, Wu CP, Su Xd, Wang SR, Liu Dg, 
Ashby CR, Huang Y, Robey RW, Liang Yj, Chen Lm, 
Shi CJ, Ambudkar SV, Chen ZS, Fu Lw. Lapatinib (Tykerb, 
GW572016) Reverses Multidrug Resistance in Cancer 
Cells by Inhibiting the Activity of ATP-Binding Cassette 
Subfamily B Member 1 and G Member 2. Cancer Research. 
2008; 68:7905–7914.
34. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, 
Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, 
Chen ZS. Erlotinib (Tarceva, OSI-774) Antagonizes ATP-
Binding Cassette Subfamily B Member 1 and ATP-Binding 
Cassette Subfamily G Member 2 Mediated Drug Resistance. 
Cancer Research. 2007; 67:11012–11020.
35. Hegedus C, Truta-Feles K, Antalffy G, Varady G, 
Nemet K, Ozvegy-Laczka C, Keri G, Orfi L, Szakacs G, 
Settleman J, Varadi A, Sarkadi B. Interaction of the EGFR 
inhibitors gefitinib, vandetanib, pelitinib and neratinib with 
the ABCG2 multidrug transporter: implications for the 
emergence and reversal of cancer drug resistance. Biochem 
Pharmacol. 2012; 84:260–267.
36. Hegedűs C, Özvegy-Laczka C, Apáti Á, Magócsi M, 
Német K, Őrfi L, Kéri G, Katona M, Takáts Z, Váradi A, 
Szakács G, Sarkadi B. Interaction of nilotinib, dasatinib 
and bosutinib with ABCB1 and ABCG2: implications 
for altered anti-cancer effects and pharmacological 
properties. British Journal of Pharmacology. 2009; 
158:1153–1164.
37. Nakanishi T, Ross DD. Breast cancer resistance protein 
(BCRP/ABCG2): its role in multidrug resistance and 
regulation of its gene expression. Chin J Cancer. 2012; 
31:73–99.
38. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast 
cancer resistance protein (BCRP/ABCG2) in cancer drug 
resistance. Biochem Pharmacol. 2012; 83:1084–1103.
39. An Y, Ongkeko WM. ABCG2: the key to chemoresistance 
in cancer stem cells? Expert opinion on drug metabolism & 
toxicology. 2009; 5:1529–1542.
40. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of 
stem cells and novel target in stem cell and cancer therapy. 
Life sciences. 2010; 86:631–637.
41. Bunting KD. ABC transporters as phenotypic markers 
and functional regulators of stem cells. Stem cells. 2002; 
20:11–20.
42. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and 
function of the human breast cancer resistance protein 
Oncotarget39291www.impactjournals.com/oncotarget
(BCRP/ABCG2). Current drug metabolism. 2010; 
11:603–617.
43. Ahmed-Belkacem A, Pozza A, Macalou S, Perez-Victoria JM, 
Boumendjel A, Di Pietro A. Inhibitors of cancer cell 
multidrug resistance mediated by breast cancer resistance 
protein (BCRP/ABCG2). Anti-cancer drugs. 2006; 
17:239–243.
44. Tamaki H, Satoh H, Hori S, Ohtani H, Sawada Y. Inhibitory 
effects of herbal extracts on breast cancer resistance protein 
(BCRP) and structure-inhibitory potency relationship of 
isoflavonoids. Drug metabolism and pharmacokinetics. 
2010; 25:170–179.
45. Nishiyama M, Kuga T. Central effects of the neurotropic 
mycotoxin fumitremorgin A in the rabbit (I). Effects on 
the spinal cord. Japanese journal of pharmacology. 1989; 
50:167–173.
46. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, 
Ambudkar SV, Dean M, McMahon JB. New inhibitors of 
ABCG2 identified by high-throughput screening. Molecular 
cancer therapeutics. 2007; 6:3271–3278.
47. Wang DS, Patel A, Sim HM, Zhang YK, Wang YJ, 
Kathawala RJ, Zhang H, Talele TT, Ambudkar SV, Xu RH, 
Chen ZS. ARRY-334543 reverses multidrug resistance by 
antagonizing the activity of ATP-binding cassette subfamily 
G member 2. J Cell Biochem. 2014; 115:1381–1391.
48. Wang DS, Patel A, Shukla S, Zhang YK, Wang YJ, 
Kathawala RJ, Robey RW, Zhang L, Yang DH, Talele TT, 
Bates SE, Ambudkar SV, Xu RH, Chen ZS. Icotinib 
antagonizes ABCG2-mediated multidrug resistance, but 
not the pemetrexed resistance mediated by thymidylate 
synthase and ABCG2. Oncotarget. 2014; 5:4529–4542.
49. Zhang H, Kathawala RJ, Wang YJ, Zhang YK, 
Patel A, Shukla S, Robey RW, Talele TT, Ashby CR Jr, 
Ambudkar SV, Bates SE, Fu LW, Chen ZS. Linsitinib 
(OSI-906) antagonizes ATP-binding cassette subfamily 
G member 2 and subfamily C member 10-mediated drug 
resistance. Int J Biochem Cell Biol. 2014; 51:111–119.
50. Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, 
Chen ZS, Chen X. Tivozanib reverses multidrug resistance 
mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). 
Future Oncol. 2014; 10:1827–1841.
51. Kuang YH, Patel JP, Sodani K, Wu CP, Liao LQ, Patel A, 
Tiwari AK, Dai CL, Chen X, Fu LW, Ambudkar SV, 
Korlipara VL, Chen ZS. OSI-930 analogues as novel 
reversal agents for ABCG2-mediated multidrug resistance. 
Biochem Pharmacol. 2012; 84:766–774.
52. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug 
transport, ATP hydrolysis, and nucleotide trapping by 
the human ABCG2 multidrug transporter. Modulation of 
substrate specificity by a point mutation. J Biol Chem. 
2002; 277:47980–47990.
53. Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JN, 
Chen ZS. Tyrosine kinase inhibitors as reversal agents for 
ABC transporter mediated drug resistance. Molecules. 
2014; 19:13848–13877.
54. Nicolle E, Boumendjel A, Macalou S, Genoux E, 
Ahmed-Belkacem A, Carrupt PA, Di Pietro A. QSAR 
analysis and molecular modeling of ABCG2-specific 
inhibitors. Adv Drug Deliv Rev. 2009; 61:34–46.
